- Market Capitalization, $K 104,091
- Shares Outstanding, K 17,763
- Annual Sales, $ 0 K
- Annual Income, $ -12,740 K
- 60-Month Beta N/A
- Price/Sales 208.18
- Price/Cash Flow N/A
- Price/Book 6.34
|Period||Period Low||Period High||Performance|
| || |
-0.45 (-7.43%)since 10/18/19
| || |
-0.05 (-0.88%)since 08/16/19
| || |
-0.49 (-8.03%)since 11/16/18
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced it has entered into a $10 million debt facility...
Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that it will report third quarter 2019 financial...
Eton Pharmaceuticals, Inc. (ETON) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that Sean Brynjelsen, Chief Executive Officer,...
Nabriva (NBRV) intends to resubmit the NDA for Contepo in Q4. The intravenous candidate is being studied for treating patients with complicated urinary tract infection including acute pyelonephritis.
--New Drug Application (NDA) Submission Expected in Fourth Quarter of 2019
Kadmon Holdings (KDMN) completes enrollment in the study of its pipeline candidate, KD025, for the treatment of chronic graft-versus-host disease (cGVHD).
Regeneron's (REGN) study on four investigational therapies for Ebola virus infection is stopped early as its therapy, REGN-EB3, was superior to Mapp Biopharmaceutical Inc.'s ZMapp in preventing death.
Epizyme (EPZM) reports wider-than-expected loss in the second quarter of 2019 and the FDA accepts the NDA for its lead pipeline candidate, tazemetostat.
Bausch (BHC) misses on both earnings and sales in the second quarter of 2019 but lifts revenue outlook on new products.